DA-1726

N/A

Report date: 2024/08/09 10:13:43
NME

Base Information

Drug NameDA-1726
Drug Alias NameDA-1726
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon receptor agonistsGlucagon-like peptide 1 receptor agonists
TargetsGlucagon receptorGlucagon-like peptide 1 receptor
Therapy Area/IndicationsObesityMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesDong-A ST Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNeurobo Pharmaceuticals IncDong-A ST Co Ltd
Inactive CompaniesN/A
Active IndicationsObesityMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A